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The article by Sendi et al. [1] describes 5
cases of prosthetic joint infection with
small colony variants (SCVs) of Staphy-
lococcus aureus for which a correct iden-
tification in the clinical microbiological
laboratory was delayed because of the un-
common morphological and physiologi-
cal properties of these organisms. Indeed,
SCVs are characterized by a strong reduc-
tion in growth rate, an atypical colony
morphology, and unusual biochemical
characteristics, which causes them to be
frequently undetected or misidentified by
standard clinical microbiology procedu-
res [2]. The difficult recovery and iden-
tification of SCVs derived from S. aureus
or other bacterial species may also ex-
plain the relatively sparse number of clin-
ical reports describing their involvement
in persistent and recurrent infections [2].
The clinical and microbiological data
presented by Sendi and colleagues sug-
gest that all 5 orthopedic patients were
initially infected with normally growing
S. aureus, which was followed by the sub-
sequent emergence of clonally related
SCV derivatives of the primary patho-
gens. Of note, the repeatedly observed
treatment failure for these prosthetic
joint infections with standard antimicro-
bial therapeutic protocols was clearly
linked with the emergence of S. aureus
SCVs. These consistent, clustered obser-
vations suggest that SCV-associated in-
fections are not exceptional events and
that their true frequency may be under-
estimated. The authors acknowledged
that a lack of awareness initially contrib-
uted to ineffective surgical revisions and
antimicrobial treatments in at least 2 of
their patients. They now recommend ac-
tively screening for SCVs when S. aureus
prosthetic joint infections persist or re-
lapse despite adequate standard antimi-
crobial therapy.
Although several genetic and metabolic
defects may contribute to SCV emergence,
a frequent, common characteristic of these
slow-growing organisms is their auxo-
trophic phenotype—namely, their require-
ment for specific substances that may
eventually restore their growth rate to the
parental level [2]. The 2 most frequently
described groups of metabolic defects in
SCV clinical isolates are those that lead
to deficient electron transport—thereby
affecting oxidative phosphorylation and
ATP generation—and those that impair
thymidine biosynthesis [2]. Because these
defects and the ensuing SCV phenotype
are often reversible (for reasons not fully
understood), this reversion in phenotype
may lead to the observation in clinical
situations of mixtures of SCVs and nor-
mally growing parental organisms. The
mixture of parental and SCV organisms
may compromize SCV isolation and
identification because of rapid over-
growth of slow-growing forms by nor-
mally growing parental organisms. Al-
though defining the precise genetic
lesion(s) in SCVs is hard to achieve, pre-
sumptive identification of the defective
metabolic pathway may be obtained by
simple detection of the auxotrophic re-
quirement(s) (e.g., hemin, menadione,
and thymidine) contributing to the SCV
phenotype, combined with assessment of
their degree of relatedness to their pa-
rental strains by molecular typing meth-
ods. The lack of specific auxotrophic test-
ing in the study by Sendi et al. [1] may
well have contributed to delayed identi-
fication of SCVs in their patients.
Of particular relevance is the observa-
tion in vitro and in vivo that exposure to
different classes of antibiotics frequently
contributes to the selection of SCVs. Aside
from an overall nonspecific decrease in an-
tibiotic susceptibility that may occur in
SCVs because of their severely reduced
growth rate and metabolic processes, some
more-specific mechanisms, such as ami-
noglycoside or trimethoprim-sulphameth-
oxazol (SXT) resistance, should be men-
tioned. The reduction in aminoglycoside
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susceptibility is caused by a decrease in
membrane potential that is linked to the
downregulation of the electron transport
chain. The clinical correlate of this ob-
servation has been the frequent isolation
of electron transport–defective S. aureus
SCVs in orthopedic patients treated with
gentamicin-containing beads, which seem
to significantly promote selection of SCVs
over normally growing S. aureus [2]. In
another clinically relevant situation, the
emergence of thymidine-dependent SCVs
derived from normally growing S. aureus
was observed in patients with cystic fi-
brosis after long-term SXT treatment [3].
The positive selection of thymidine-
dependent SCVs is currently explained by
the stimulated uptake of extracellular
thymidine that bypasses the SXT-inhib-
ited pathway [2]. Interestingly, SCV iso-
lates from 2 patients in Sendi and col-
leagues’ study were resistant to SXT
without prior clinical exposure to these
antimicrobials, although their thymidine
auxotrophy could not be experimentally
assessed.
An additional key property of SCVs is
their increased ability to survive within
nonprofessional phagocytes, such as epi-
thelial cells, fibroblasts, osteoblasts, and
endothelial cells [2]. S. aureus is not tra-
ditionally considered to be an intracellular
pathogen; however, over the last decade,
published evidence of SCVs’ ability to sur-
vive intracellularly has increased, from a
few sporadic reports to, at present, a myr-
iad of model systems that report bacterial
uptake and persistence within nonprofes-
sional phagocytes. Most of these studies
reported cytopathological effects of intra-
cellular S. aureus, but only a few of these
studies specifically addressed the under-
lying mechanisms of intracellular sur-
vival. Notable advances include the report
that intracellular S. aureus may persist in
epithelial cells and may serve as reser-
voirs for recurrent infections in cases of
chronic rhinosinusitis [4]. One explana-
tion for the improved intracellular survival
of SCVs is their decreased overall metab-
olism and dampened production of cy-
totoxins, which may downregulate the in-
duction of cell lysis or apoptosis [2]. Their
intracellular location, combined with the
lack of efficient bactericidal mechanisms
in nonprofessional phagocytes, are as-
sumed to protect SCVs from professional
phagocytes and from antimicrobial agents
whose action is mainly extracellular. In
their report, Sendi et al. [1] showed the
presence of numerous intracellular staph-
ylococci within fibroblasts, as visualized by
transmission electron microscopy in re-
peated biopsy samples from a single pa-
tient. Although the authors assume that
these intracellular cocci truly represent
SCVs on the basis of microbiological ar-
guments that the same biopsy speci-
mens yielded pure SCV cultures, these
transmission electron microscopy–derived
conclusions should be regarded as prelim-
inary, because the quality of the micro-
graphs does not allow for the differenti-
ation of SCVs from normally growing
bacteria, compared with previous reports
[2, 5]. Despite these limitations, the clin-
ical transmission electron microscopy ob-
servations of intracellular S. aureus res-
ervoirs as potential sources of persistent
and recurrent infection confirm the great
versatility and fitness adjustment of S. au-
reus to escape the strong selective pressure
of bactericidal antibiotics and phagocytic
clearance mechanisms through intracel-
lular location and a quiescent lifestyle.
Progress in understanding SCV infec-
tions has been recently aided by detailed
studies of regulatory and phenotypic
properties [2], as well as an appreciation
of enhanced surface expression of fibro-
nectin-binding proteins that favor cell in-
vasion kinetics [6]. Of particular note is
the fact that 80% of debilitating human
osteomyelitis infections are attributed to
S. aureus that can invade and persist
within osteoblasts [7, 8]. Apart from the
anatomical and physiological characteris-
tics of bone, which make antibiotic treat-
ment of these infections challenging, is the
realization that, if S. aureus persists intra-
cellularly for 112 h, bacteria acquire sig-
nificantly altered susceptibilities to anti-
biotics [7]. Knowledge of the underlying
molecular mechanisms that permit sur-
vival and intracellular persistence of S. au-
reus is largely unexplored and would ap-
pear to be an urgent priority.
Although SCVs were considered for de-
cades to produce essentially subacute, an-
tibiotic-resistant infections, there is now
increasing evidence that this may be just
1 part of a normal life cycle of staphylo-
cocci, with frequent switches from slow-
growing to normally growing cells and
vice versa [2]. In addition to recent ex-
perimental studies that have revealed some
unsuspected virulence properties of SCVs
in animal models of septic arthritis and
endocarditis [2], clinical observations by
Sendi and colleagues of bacteremia and
bacteremic seeding from 1 hip prosthesis
to the contralateral side in 2 patients seem
to support the concept of an infectious
cycle with alternating subacute and acute
phases. Eventual confirmation of this life
cycle model may explain the great diffi-
culty in eradicating serious S. aureus in-
fections with antimicrobial therapy. In-
deed, the available antibiotic options for
treating SCVs alone or in mixtures with
normally growing cells are very limited
and are further compromised by a high
risk of emergence of antibiotic resis-
tance. To target SCVs, antimicrobial agents
should be able to penetrate host cells that
contain bacteria and exert optimal intra-
cellular bactericidal activity, especially
against slowly growing bacteria. Rifam-
pin is the single antistaphylococcal agent
considered to be effective for treating
intracellular infections, but its use in
monotherapy is compromised by rapid
emergence of high-level resistance. The
combined regimen of rifampin with a flu-
oroquinolone, as proposed by Sendi et al.
[1], may be the only available option, but
this choice seems inadequate for treat-
ing methicillin-resistant S. aureus isolates,
which are generally resistant to fluoro-
quinolones. Accordingly, the development
of more-elaborate in vitro assays to reli-
ably predict the outcome of antimicrobial
therapy against SCVs is urgently needed.
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